Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-LOXL2, AB0024 Vector   (CAT#: GTVCR-WQ138MR)

This product GTVCR-WQ138MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting LOXL2. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Humanized
RefSeq NM_002318.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 4017
UniProt ID Q9Y4K0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-LOXL2, AB0024 Vector (GTVCR-WQ138MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1754MR IVTScrip™ pSP6-VEE-mRNA-Anti-SOST, LY2541546 Vector Vector LY2541546
GTVCR-WQ876MR IVTScrip™ pT7-VEE-mRNA-Anti-CD22, CAT-8015 Vector Vector CAT-8015
GTVCR-WQ1261MR IVTScrip™ pSP6-VEE-mRNA-Anti-HBV, GC-1102 Vector Vector GC-1102
GTVCR-WQ784MR IVTScrip™ pT7-VEE-mRNA-Anti-FGFR1, BMS-986036 Vector Vector BMS-986036
GTVCR-WQ1785MR IVTScrip™ pSP6-VEE-mRNA-Anti-S, LY-3819253 Vector Vector LY-3819253
GTVCR-WQ2326MR IVTScrip™ pSP6-VEE-mRNA-Anti-PDGFRB, REGN-2176 Vector Vector REGN-2176
GTVCR-WQ1642MR IVTScrip™ pSP6-VEE-mRNA-Anti-PCSK9, JS002 Vector Vector JS002
GTVCR-WQ1231MR IVTScrip™ pT7-VEE-mRNA-Anti-VTCN1, FPA-150 Vector Vector FPA-150
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW